DUBLIN, Nov. 29, 2016
-- Allergan plc (NYSE:AGN) a leading global pharmaceutical company, today announced that Brent Saunders, Allergan's Chairman, CEO and President, will participate in a fireside chat at the
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
The presentation will be webcast live and can be accessed on Allergan's Investor Relations web site at http://ir.allergan.com. The webcast can also be accessed through the following http://www.veracast.com/webcasts/citigroup/healthcare2016/68205190244.cfm
An archived version of the webcast will be available approximately two hours after the live presentation ends and can be accessed at the same locations for 180 days.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
CONTACTS:Allergan:Investors:Lisa DeFrancesco(862) 261-7152 Media:Mark Marmur(862) 261-7558
CONTACTS:Allergan:Investors:Lisa DeFrancesco(862) 261-7152
Media:Mark Marmur(862) 261-7558
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-to-present-at-2016-citi-global-healthcare-conference-300369534.html
SOURCE Allergan plc
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All